Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which steroid works best for thick, itchy skin plaques?

NCT ID NCT07666620

Disease control Sponsor: Noor Aziz Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two standard steroid treatments for hypertrophic lichen planus, a chronic skin condition that causes thick, intensely itchy plaques. Fifty adults will be randomly assigned to apply a strong steroid cream twice daily for 12 weeks or receive steroid injections into the lesions every 4 weeks. The goal is to see which approach better reduces plaque thickness and itching.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Clobetasol propionate 0.05% cream and triamcinolone acetonide injection
What this could lead to
If this trial succeeds, it could show which standard steroid treatment works better for reducing plaque thickness and itching in hypertrophic lichen planus.
What could go wrong
This is a small, early-phase trial with only 50 participants, so results may not apply to everyone. Both treatments are already used, so no major breakthrough is expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \>= 18 years, both genders\[cite: 1\] * Confirmed clinically as hypertrophic lichen planus with Lichen Planus Severity Index (LPSI) score \>= 2 at baseline and Pruritus Visual Analog Scale (VAS) score \>= 4 at baseline\[cite: 1\] * No use of topical or intralesional treatment of lichen planus within the last 4 weeks\[cite: 1\] * Able to provide written informed consent in English or Urdu language\[cite: 1\] Exclusion Criteria: * Drug-induced lichenoid lesions\[cite: 1\] * Pregnant or lactating women\[cite: 1\] * Uncontrolled diabetes mellitus or any other active skin infections\[cite: 1\] * Necessity of systemic corticosteroids or immunosuppressive drugs as the primary treatment\[cite: 1\] * Previous history of hypersensitivity or sensitivity to the study medicines (clobetasol propionate or triamcinolone acetonide)\[cite: 1\] * Refusal to provide informed consent\[cite: 1\]

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypertrophic lichen planus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hypertrophic lichen planus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypertrophic lichen planus

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Dermatology, Combined Military Hospital (CMH)

    Abbottabad, Khyber Pakhtunkhua, 21200, Pakistan